{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:09:24Z","timestamp":1793084964732,"version":"4.5.0"},"reference-count":32,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>BRAF inhibitors have a 50\u201370% response rate in melanoma but are less effective for thyroid cancer. Differential response may be from activation or expression of downstream mitogen-activated protein kinase (MAPK) pathway genes. Retrospective analysis compared whole exome and transcriptome sequencing in melanoma and thyroid cancers from April 2019 to October 2023. The MAPK Activation Score (MPAS) was calculated using Z-score normalized\/log-transformed values indicating expression across 10 MAPK-associated genes. Our tumor registry provided outcome data. BRAF V600E mutations were identified in 33 of 200 (17%) melanomas and 14 (7%) had other BRAF mutations (V600K\/R). Of 49 thyroid tumor samples, BRAF V600E mutations were found in 19 (39%). RNA expression of BRAF and the 10 MAPK-associated genes were increased in melanomas with V600E compared to wild-type BRAF (p = 0.02). Conversely, BRAF V600E mutation in thyroid cancer was not associated with increased expression nor MAPK pathway activation. No significant difference in overall survival based on BRAF mutation was observed in the subset of patients where data was available. The MAPK pathway is differentially affected by the different cancers, with increased MAPK activation observed in melanoma and not in thyroid cancer. This may account in part for the observed differential response to BRAF inhibitors.<\/jats:p>","DOI":"10.3390\/ijms26167910","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T16:22:33Z","timestamp":1755534153000},"page":"7910","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-894X","authenticated-orcid":false,"given":"Sourat","family":"Darabi","sequence":"first","affiliation":[{"name":"Hoag Family Cancer Institute, Newport Beach, CA 92663, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-9036","authenticated-orcid":false,"given":"Phillip","family":"Stafford","sequence":"additional","affiliation":[{"name":"Hoag Family Cancer Institute, Newport Beach, CA 92663, USA"},{"name":"School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA"},{"name":"Fulgent Genetics, El Monte, CA 91731, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Braxton","sequence":"additional","affiliation":[{"name":"Hoag Family Cancer Institute, Newport Beach, CA 92663, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1608-3683","authenticated-orcid":false,"given":"Carlos E.","family":"Zuazo","sequence":"additional","affiliation":[{"name":"Hoag Family Cancer Institute, Newport Beach, CA 92663, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor J.","family":"Brodie","sequence":"additional","affiliation":[{"name":"Hoag Family Cancer Institute, Newport Beach, CA 92663, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Demeure","sequence":"additional","affiliation":[{"name":"Hoag Family Cancer Institute, Newport Beach, CA 92663, USA"},{"name":"Translational Genomics Research Institute, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Roa, P., Bremer, N.V., Foglizzo, V., and Cocco, E. (2024). Mutations in the Serine\/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors. Cancers, 16.","DOI":"10.20944\/preprints202401.1957.v2"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Savoia, P., Fava, P., Casoni, F., and Cremona, O. (2019). Targeting the ERK Signaling Pathway in Melanoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061483"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Priantti, J.N., Vilbert, M., Madeira, T., Moraes, F.C.A., Hein, E.C.K., Saeed, A., and Cavalcante, L. (2023). Efficacy and Safety of Rechallenge with BRAF\/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15153754"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ejca.2012.11.004","article-title":"BRAF inhibitor activity in V600R metastatic melanoma","volume":"49","author":"Klein","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1530\/EC-21-0410","article-title":"BRAF V600E mutation in papillary thyroid carcinoma: It\u2019s relation to clinical features and oncologic outcomes in a single cancer centre experience","volume":"10","author":"Iskanderian","year":"2021","journal-title":"Endocr. Connect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/pcm.2019.09.04","article-title":"Precision medicine: BRAF mutations in thyroid cancer","volume":"2","author":"Podolski","year":"2019","journal-title":"Precis. Cancer Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/thy.2014.0123","article-title":"BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer","volume":"25","author":"Falchook","year":"2015","journal-title":"Thyroid"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: A non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-018-0051-4","article-title":"A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types","volume":"2","author":"Wagle","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/fon-2019-0748","article-title":"Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer","volume":"16","author":"Huijberts","year":"2020","journal-title":"Future Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/1078-0432.CCR-18-1680","article-title":"Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma","volume":"25","author":"Wang","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/SLA.0b013e318148563d","article-title":"The prevalence and prognostic value of BRAF mutation in thyroid cancer","volume":"246","author":"Kebebew","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2200107","DOI":"10.1200\/PO.22.00107","article-title":"Clinical Activity of Mitogen-Activated Protein Kinase\u2013Targeted Therapies in Patients With Non\u2013V600 BRAF-Mutant Tumors","volume":"6","author":"Dankner","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_18","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_19","unstructured":"U.S. Food and Drug Administration (2022). FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for Unresectable or Metastatic Solid Tumors with BRAF V600E Mutation."},{"key":"ref_20","unstructured":"Stenger, M. (2022). Dabrafenib in Combination with Trametinib for Unresectable or Metastatic Solid Tumors with BRAF V600E Mutation, The ASCO Post."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e404770","DOI":"10.1200\/EDBK_404770","article-title":"Expanding the Benefit: Dabrafenib\/Trametinib as Tissue-Agnostic Therapy for BRAF V600E\u2013Positive Adult and Pediatric Solid Tumors","volume":"43","author":"Gouda","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-13-0131","article-title":"D\u00e9j\u00e0 Vu: EGF receptors drive resistance to BRAF inhibitors","volume":"3","author":"Girotti","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2014.09.041","article-title":"Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes","volume":"148","author":"Sinicrope","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re activation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/erc.1.0978","article-title":"BRAF mutation in thyroid cancer","volume":"12","author":"Xing","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rusinek, D., Swierniak, M., Chmielik, E., Kowal, M., Kowalska, M., Cyplinska, R., Czarniecka, A., Piglowski, W., Korfanty, J., and Chekan, M. (2015). BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143688"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Byron, A., Bernhardt, S., Ouine, B., Cartier, A., Macleod, K.G., Carragher, N.O., Sibut, V., Korf, U., Serrels, B., and de Koning, L. (2020). Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-77335-0"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12020-022-03004-z","article-title":"Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer","volume":"76","author":"Gouda","year":"2022","journal-title":"Endocrine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1158\/0008-5472.CAN-06-3312","article-title":"Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma","volume":"67","author":"Kumar","year":"2007","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jid.2014.418","article-title":"Epigenetic changes of EGFR have an important role in BRAF inhibitor\u2013resistant cutaneous melanomas","volume":"135","author":"Wang","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","unstructured":"(2024, January 2\u20135). Podium Presentation. Proceedings of the Western Surgical Association 132nd Scientific Session, Colorado Springs, CO, USA."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/7910\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:29:01Z","timestamp":1760034541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/7910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":32,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ijms26167910"],"URL":"https:\/\/doi.org\/10.3390\/ijms26167910","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]}}}